Clients

Small Emerging Pharmaceutical /Bbiotech Companies (Worldwide)

General advice on synthesis, process R&D, scale-up, kilogram supply of API, regulatory/quality/specification CMC and formulation issues, and project management when necessary. The list below is not exhaustive, but illustrates the services we have provided over the years to our clients in this group:

•   Choice of CRO/CMO
•   Material supply
•   Trouble Shooting
•   Salt selection, polymorphism and crystallisation issues

Virtual Pharmaceutical Development Companies (UK/USA)

Projects covering discovery to out-license and launch.

Examples of services to clients in the group include:

• Compilation of CMC package
• Auditing CMOs
• Recommending manufacturing partners

Major Pharmaceutical Company (USA)

Trevor Laird sits on the Science Advisory Board

Small, independent, well established Pharmaceutical Company (Europe)

The service provided has included:

• 2-4 visits per year since 2002
• Reviewing all current PRD projects covering any of the competencies above as required
• Giving literature highlights and training presentations

General API Manufacturer (USA)

We have given advice on cost-effective routes and scale-up as well as literature highlights and training presentations

Major Pharmaceutical Company (USA)

The service provided has included:

• 3 visits per year since 1997
• Reviewing all current PRD projects covering any of the competencies above as required
• Writing follow-up report after each visit

Generic Pharmaceutical Manufacturers

The services provided have included:

• Advice on chemical development and scale up
• Troubleshooting
• Manufacture of desired physical form, polymorph and particle size

Technology Companies and Universities

Scientific Update consultants, having a wide knowledge of the business of fine chemicals and pharmaceuticals, are often asked to carry out detailed market analysis, which may investigate the potential for a new product or technology.

Recent surveys have included studies on biocatalysis (2 studies, one on the potential for a novel enzyme group, the other on the need for intermediate scale biotransformation facilities), removal of heavy metals from pharmaceuticals, and the need for additional polymorphism screening facilities.

These studies have been carried out in collaboration with other consultants, where appropriate.